Johnson & Johnson (JNJ.DU)
| Previous close | 135.30 |
| Open | 135.60 |
| Bid | 135.36 x N/A |
| Ask | 135.68 x N/A |
| Day's range | 135.30 - 135.60 |
| 52-week range | 132.72 - 160.80 |
| Volume | |
| Avg. volume | 11 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
BenzingaJohnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
Monday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM). Results from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated with Tecvayli at the recommended Phase 2 dose demonstrated an overall response rate (ORR) of 63%, with responses continuing to deepen and 46% of patients achieving a complet
ZacksImprove Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
